首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 156 毫秒
1.
目的:探讨赖氨酸脱甲基酶2A(Lysine-specific demethylase 2A,KDM2A)对顺铂(cisplatin,DDP)耐药的人卵巢癌细胞A2780细胞增殖和凋亡的影响及其可能作用机制。方法:通过构建慢病毒载体转染A2780/DDP,分为A2780、A2780/DDP、A2780/DDP/KDM2A(转染KDM2A)、A2780/DDP/Jagged1(转染Jagged1)以及A2780/DDP/NC(转染病毒载体)组。采用Western blot检测3组KDM2A、Jagged1、Bcl2和BAX蛋白表达,CCK8和平板克隆形成实验检测细胞对顺铂的敏感性,流式细胞术检测细胞凋亡情况。结果:A2780/DDP细胞KDM2A和Jagged1的蛋白表达水平均显著高于A2780细胞(P0.05),且A2780/DDP/KDM2A细胞中KDM2A和Jagged1的蛋白表达均低于A2780/DDP以及阴性对照组A2780/DDP/NC(P0.05);A2780/DDP/Jagged1细胞的Jagged1蛋白表达低于A2780/DDP以及A2780/DDP/NC(P0.05),而其KDM2A蛋白的表达比较差异无统计学意义(P0.05)。不同浓度DDP处理的A2780/DDP/KDM2A细胞的生长抑制率均显著高于A2780/DDP/NC和A2780/DDP细胞(P0.05),A2780/DDP/KDM2A细胞克隆形成数量亦明显高于A2780/DDP/NC和A2780/DDP细胞(P0.05)。A2780/DDP/KDM2A细胞凋亡率为(25.84±3.27)%,明显高于A2780/DDP细胞[(14.29±1.96)%](P0.05)和A2780/DDP/NC细胞[(12.46±2.15)%](P0.05)。A2780/DDP/KDM2A细胞中Bcl-2蛋白表达明显低于A2780/DDP细胞(P0.05),而A2780/DDP/KDM2A细胞Bax的表达水平却高于A2780/DDP细胞(P0.05)。结论:KDM2A可能通过上调Jagged1的表达,促进人卵巢癌细胞A2780的增殖并抑制其凋亡,进而降低人卵巢癌耐药细胞A2780的顺铂敏感性。  相似文献   

2.
目的:研究CRM197对裸鼠卵巢癌移植瘤生长的抑制作用探讨其对逆转卵巢癌组织耐药作用及其在卵巢癌治疗中的可行性.方法:用人卵巢癌亲本细胞A2780、耐紫杉醇细胞A2780/Taxol及耐顺铂细胞A2780/DDP分别建立裸鼠卵巢癌移植瘤模型,观察注射CRM197组与阴性对照组裸鼠肿瘤生长情况,免疫组化法测定各组裸鼠肿瘤组织中HB-EGF及P-gp表达情况.结果:HB-EGF及P-gp在各肿瘤组织中不同程度的表达,在注射CRM197的裸鼠肿瘤组织中表达明显降低(P<0.05),差异具有统计学意义.结论:CRM197通过抑制肝素结合表皮生长因子的信号传导通路激活抑制了裸鼠卵巢癌移植瘤的生长,使裸鼠卵巢癌移植瘤HB-EGF及P-gp表达明显降低.  相似文献   

3.
目的:探究干扰人白血病相关蛋白16(LRP16)基因表达对人卵巢癌耐药SKOV3/DDP细胞耐药性的影响及其相关机制。方法:采用Real-time PCR和蛋白免疫印迹(WB)检测LRP16在敏感组(SKOV3细胞)、耐药组(SKOV3/DDP细胞)、LRP16干扰组(SKOV3/DDP细胞-稳定转染LRP16 shRNA质粒)和NC组(即阴性对照组,SKOV3/DDP细胞-稳定转染阴性对照质粒)细胞中的表达情况;MTT试验检测LRP16对SKOV3/DDP细胞耐药性的影响;彗星试验检测LRP16对顺铂(DDP)诱导DNA损伤的影响;流式细胞术(FCM)试验检测细胞凋亡变化;WB试验检测PTEN、p-Akt和NF-κB蛋白表达水平。结果:LRP16干扰组细胞的耐药指数(RI)值(3.19±0.21)显著低于耐药组细胞(6.84±0.37)(P0.05)。DDP(25μmol/L)处理24 h后,LRP16干扰组DNA损伤的细胞百分比、细胞凋亡百分比均显著低于耐药组和NC组(P均0.05),而耐药组和NC组比较差异无统计学意义(P0.05);LRP16干扰组细胞PTEN蛋白相对表达量高于耐药组和NC组(P均0.05),而p-Akt和NF-κB相对表达量低于耐药组和NC组(P均0.05)。结论:干扰LRP16基因表达可逆转卵巢癌耐药SKOV3/DDP细胞的耐药性,PTEN/Akt/NF-κB可能是其中的关键信号通路。  相似文献   

4.
摘要 目的:探讨人卵巢癌顺铂耐药细胞株CP70沉默S100A4 基因后,CP70细胞对顺铂敏感性、凋亡及细胞迁移的影响。方法:设计并合成S100A4基因特异性的siRNA并转染入卵巢癌细胞CP70,48 h后应用RT-PCR和Western Blot检测在mRNA和蛋白水平siRNA对S100A4的影响,MTT法检测转染 siRNA后卵巢癌细胞CP70对顺铂敏感性的变化。;用流式细胞术检测顺铂(40 μM) 对转染S100A4 siRNA后对卵巢癌细胞CP70凋亡的影响,Transwell法观察siRNA抑制S100A4后对卵巢癌CP70迁移能力的影响。 结果:与空白对照组、阴性对照组相比,S100A4 siRNA转染组CP70细胞的S100A4基因和蛋白表达降低(P<0.01)。MTT法检测顺铂敏感性发现S100A4 siRNA转染组CP70细胞顺铂敏感性增强。在顺铂刺激下,siRNA转染组细胞凋亡率高于其他各组,差异具有统计学意义(P<0.05)。Transwell发现CP70细胞迁移能力明显下降(P<0.05)。结论:S100A4 siRNA能够明显抑制CP70细胞S100A4的表达,从而增强细胞对顺铂的敏感性,促进细胞凋亡,减弱细胞的迁移能力。S100A4有望成为逆转卵巢癌铂类耐药的治疗靶点。  相似文献   

5.
构建携带错配修复基因hMLH1编码序列全长的真核表达质粒pCAN—hMLHl,并探讨其对卵巢癌细胞顺铂耐药的逆转作用。应用基因重组技术将pET28-hMLHl中的目的基因hMLHl定向克隆到真核表达载体pCAN,经酶切及测序鉴定:分别将pCAN—hMLHl和空质粒pCAN转染进卵巢癌耐药细胞SKOV3/DDP,同时以对顺铂敏感的sKOV3细胞和未转染的SKOV3/DDP细胞作为对照:应用RT-PCR和Westemblo凇测转染前后细胞内hMLHlmRNA和蛋白的表达变4Jc;四甲基偶氮唑蓝(MTT)比色法检测转染前后sKOv3/DDP细胞对顺铂敏感性的变化;Hoechst染色检测转染前后细胞的凋亡。结果提示:pCAN—hMLHl重组质粒经酶切及测序鉴定,表明真核表达质粒构建正确;采用脂质体法转染sKOv3/DDP细胞后,RT-PCR和Westernblot检测到耐药细胞内hMLHl的表达增强:MTT结果显示转染重组质粒后sKOv3/DDP细胞对顺铂的敏感性显著增加;Hoechst染色观察到转染后耐药细胞的凋亡明显增强。该研究成功构建了pCAN.hMLHl重组质粒,在sKOV3/DDP细胞中进行表达,并能增强耐药细胞对顺铂的敏感性,促进耐药细胞的凋亡。  相似文献   

6.
许欣  辛晓燕  李佳  刘海霞  魏翻艳 《生物磁学》2014,(13):2401-2404
目的:探讨人卵巢癌顺铂耐药细胞株CP70沉默S100A4基因后,CP70细胞对顺铂敏感性、凋亡及细胞迁移的影响。方法:设计并合成S100A4基因特异性的siRNA并转染入卵巢癌细胞CP70,48 h后应用RT-PCR和Western Blot检测在mRNA和蛋白水平siRNA对S100A4的影响,MTT法检测转染siRNA后卵巢癌细胞CP70对顺铂敏感性的变化。用流式细胞术检测顺铂(40μM)对转染S100A4 siRNA后对卵巢癌细胞CP70凋亡的影响,Transwell法观察siRNA抑制S100A4后对卵巢癌CP70迁移能力的影响。结果:与空白对照组、阴性对照组相比,S100A4siRNA转染组CP70细胞的S100A4基因和蛋白表达降低(P〈0.01)。MTT法检测顺铂敏感性发现S100A4 siRNA转染组CP70细胞顺铂敏感性增强。在顺铂刺激下,siRNA转染组细胞凋亡率高于其他各组,差异具有统计学意义(P〈0.05)。Transwell发现CP70细胞迁移能力明显下降(P〈0.05)。结论:S100A4 siRNA能够明显抑制CP70细胞S100A4的表达,从而增强细胞对顺铂的敏感性,促进细胞凋亡,减弱细胞的迁移能力。S100A4有望成为逆转卵巢癌铂类耐药的治疗靶点。  相似文献   

7.
为了研究大黄素对人卵巢癌耐药细胞株SKOV3/DDP细胞耐药逆转作用及其机制,本研究以卵巢癌SK-OV3和多药耐药细胞株SKOV3/DDP为研究对象,通过噻唑蓝(MTT)法测定SKOV3/DDP细胞的耐药指数和大黄素在无细胞毒浓度下对卵巢癌细胞耐受顺铂(DDP)的逆转作用;采用Real-time PCR技术检测耐药相关基因HIF-1α、STAT1、CK2α、GSTP1 mRNA表达情况。结果发现无细胞毒作用浓度的7.8 mg/L和3.9 mg/L大黄素能逆转SKOV3/DDP细胞对DDP的耐药性,对DDP的逆转倍数分别为1.91倍和1.30倍,与SKOV3比较,SKOV3/DDP细胞的HIF-1α、STAT1、CK2α、GSTP1 mRNA表达明显升高(P<0.01)。3.9 mg/L和7.8 mg/L大黄素作用均可下调HIF-1α、CK2α、STAT1 mRNA表达,存在剂量-效应依赖关系。7.8 mg/L大黄素作用可下调GSTP1 mR-NA表达,但3.9 mg/L大黄素作用不明显。7.8 mg/L和3.9 mg/L大黄素联合IC50浓度的DDP时,四个耐药相关基因的表达与单独化疗药组作用相比明显下调(P<0.01)。提示无细胞毒浓度的大黄素对卵巢癌细胞耐药逆转的作用可能是通过下调HIF-1α、STAT1、GSTP1、CK2α的表达起作用。  相似文献   

8.
目的:探讨dbp A蛋白在卵巢癌组织中的表达及其对卵巢癌细胞增殖的影响。方法:通过荧光定量和蛋白质免疫印迹方法检测临床卵巢癌组织和正常癌旁组织中dbp A的表达量;设计合成针对dbp A基因的双链小干扰RNA转染人卵巢癌细胞系SKOV3和A2780细胞,用荧光定量和蛋白质免疫印迹方法检测细胞中dbp A的表达量,MTT法和克隆形成试验检测细胞的增殖能力和克隆形成能力,流式细胞术检测各组细胞周期和细胞凋亡的变化。结果:dbp A在卵巢癌组织、SKOV3和A2780细胞中表达较癌旁正常卵巢组织显著升高。沉默dbp A后,SKOV3和A2780细胞中dbp A蛋白表达量显著降低,SKOV3和A2780细胞增殖能力和克隆形成能力显著下降(P0.05),G0/G1期细胞百分比显著增加(P0.01),S期细胞百分比明显减少(P0.05),细胞凋亡率显著升高(P0.01)。结论:dbp A在卵巢癌组织和卵巢癌细胞SKOV3和A2780中过表达,沉默dbp A基因后可抑制SKOV3和A2780细胞的增殖能力和克隆形成能力。  相似文献   

9.
目的:探究5-氮杂-2’-脱氧胞苷体外逆转卵巢癌铂类耐药细胞系CP70对顺铂的耐药性,并探讨与SOCS-2表达的关系。方法:免疫细胞化学和Western blot方法检测使用5-氮杂-2’-脱氧胞苷处理细胞前后细胞内SOCS-2表达水平。MTT法检测单独使用5-氮杂-2’-脱氧胞苷或顺铂及两药联合使用对CP70细胞的抑制作用。结果:两药联合处理CP70细胞后顺铂耐药逆转倍数为1.34、1.63、2.34,联合处理组的细胞中SOCS-2表达明显升高。结论:5-氮杂-2’-脱氧胞苷可以部分逆转CP70细胞对顺铂的耐药性,且此作用可能与增加细胞的SOCS-2表达有关。  相似文献   

10.
为了探讨卵巢癌中HMGB1、BRCA1和p62蛋白的表达与化疗敏感性的相关性,培养卵巢癌顺铂化疗耐药细胞ES-2和敏感细胞SKVO3,顺铂100 mg/m2环境培养5 d,分别采用Western blotting法和RT-PCR方法检测两种细胞中的HMGB1、BRCA1和p62蛋白表达情况,采用流式细胞术测算细胞凋亡率。敏感组细胞SKOV3和耐药组细胞ES-2中,BRCA1蛋白表达率分别为(38.08±22.56)%和(45.65±22.42)%,HMGB1蛋白表达率分别为(75.13±16.45)%和(83.08±24.22)%,p62蛋白表达率分别为(52.31±25.13)%和(37.26±21.09)%;顺铂处理后,敏感组SKOV3细胞中BRCA1蛋白表达量显著提高(p0.05),耐药组ES-2细胞中p62蛋白相对表达量高于敏感组SKOV3细胞(p0.01)。卵巢癌化疗后HMGB1下调与BRCA1、p62上调共存;卵巢癌中BRCA1蛋白的不同表达与化疗敏感性相关,其水平变化有可能作为一种新的肿瘤标志物,动态观察卵巢癌病情进展,为临床治疗提供客观指标。  相似文献   

11.
Chemoresistance is a major therapeutic obstacle in cancer patients, and the mechanisms of drug resistance are not fully understood. In the present study, we established platinum-resistant human ovarian cancer cell lines and identified differentially expressed proteins related to platinum resistance. The total proteins of two sensitive (SKOV3 and A2780) and four resistant (SKOV3/CDDP, SKOV3/CBP, A2780/CDDP, and A2780/CBP) human ovarian cancer cell lines were isolated by two-dimensional gel electrophoresis (2-DE). The differentially expressed proteins were identified using matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS). In total, 57 differential protein spots were identified, and five proteins, including annexin A3, destrin, cofilin 1, Glutathione-S-transferase omega 1 (GSTO1-1), and cytosolic NADP+-dependent isocitrate dehydrogenase (IDHc), were found to be co-instantaneous significance compared with their parental cells. The expression of the five proteins was validated by quantitative PCR and western blot, and the western blot results showed complete consistency with proteomic techniques. The five proteins are hopeful to become candidates for platinum resistance. These may be useful for further study of resistance mechanisms and screening of resistant biomarkers.  相似文献   

12.
Yu W  Jin C  Lou X  Han X  Li L  He Y  Zhang H  Ma K  Zhu J  Cheng L  Lin B 《PloS one》2011,6(12):e29450
Cisplatin resistance is one of the major reasons leading to the high death rate of ovarian cancer. Methyl-Capture sequencing (MethylCap-seq), which combines precipitation of methylated DNA by recombinant methyl-CpG binding domain of MBD2 protein with NGS, global and unbiased analysis of global DNA methylation patterns. We applied MethylCap-seq to analyze genome-wide DNA methylation profile of cisplatin sensitive ovarian cancer cell line A2780 and its isogenic derivative resistant line A2780CP. We obtained 21,763,035 raw reads for the drug resistant cell line A2780CP and 18,821,061reads for the sensitive cell line A2780. We identified 1224 hyper-methylated and 1216 hypomethylated DMRs (differentially methylated region) in A2780CP compared to A2780. Our MethylCap-seq data on this ovarian cancer cisplatin resistant model provided a good resource for the research community. We also found that A2780CP, compared to A2780, has lower observed to expected methylated CpG ratios, suggesting a lower global CpG methylation in A2780CP cells. Methylation specific PCR and bisulfite sequencing confirmed hypermethylation of PTK6, PRKCE and BCL2L1 in A2780 compared with A2780CP. Furthermore, treatment with the demethylation reagent 5-aza-dC in A2780 cells demethylated the promoters and restored the expression of PTK6, PRKCE and BCL2L1.  相似文献   

13.
Tai J  Cheung S  Wu M  Hasman D 《Phytomedicine》2012,19(5):436-443
Rosemary (Rosmarinus officinalis L.) is a popular culinary/medicinal herb. Recent studies have shown it has pharmacologic activities for cancer chemoprevention and therapy. This study evaluated the antiproliferation activity of rosemary extract (RE) against human ovarian cancer cells, and whether the extract and its three main active ingredients carnosol (CS), carnosic acid (CA) and rosmarinic acid (RA) can enhance the antiproliferation activity of cisplatin (CDDP). Our study showed that RE has significant antiproliferation activity on human ovarian cancer A2780 and its CDDP resistant daughter cell line A2780CP70, with IC(50) (50% inhibitory concentration) estimated at 1/1000 and 1/400 dilutions respectively. RE enhanced the antiproliferation effect with CDDP on both A2780 and A2780CP70 cells. A2780 cells were consistently more sensitive to CS, CA, and RA than A2780CP70 cells between 2.5 and 20μg/ml. CS and RA also showed synergistic antiproliferation effect with CDDP on A2780 cells at some concentrations. RE treated by ultrafiltration, dialysis, and removal of phenolics lost the antiproliferation activity suggested that the activity resides in phenolics with MW<1000Da. Apoptosis array study of A2780 cells treated with RE showed that the expression of a number of genes regulating apoptosis were modulated by the treatment. This study showed that RE inhibited the proliferation of ovarian cancer cell lines by affecting the cell cycle at multiple phases. It induced apoptosis by modifying the expression of multiple genes regulating apoptosis, and holds potential as an adjunct to cancer chemotherapy.  相似文献   

14.
The green tea polyphenol epigallocatechin-3-gallate (EGCG) has cancer chemopreventive properties against various types of cancers. The compound is known to attack various targets in transformed cells. In this report, we examined the action of EGCG on ovarian cancer cells. Eight ovarian cancer cell lines were tested (SKOV3, CAOV3, OVCAR3, OVCAR10, A2780, CP70, C30, and C200) and showed IC50s for EGCG at the micromolar range, including ones that are resistant to the chemotherapeutic drug cisplatin. The ovarian cancer cells were sensitive to H2O2 at similar concentrations, and EGCG treatment led to enhanced intracellular H2O2. Neutralization with pyruvate, a scavenger of H2O2, suggests that the toxicity of EGCG may be mediated by oxidative stress from the free radical. Addition of Tempol, a superoxide dismutase mimetic, demonstrates that H2O2 might be generated endogenously from superoxide. The toxicity of cisplatin and the development of cisplatin resistance are major obstacles in treatment of ovarian cancer. We found that addition of EGCG amplified the toxicity of cisplatin. EGCG increased cisplatin potency by three to six-fold in SKOV3, CAOV3, and C200 cells, the latter being a cell line induced to have several hundred fold resistant to cisplatin above the parental line. Our findings suggest that EGCG may accentuate oxidative stress to inhibit growth of ovarian cancer cells and sensitize them to cisplatin.  相似文献   

15.
Dai Z  Yin J  He H  Li W  Hou C  Qian X  Mao N  Pan L 《Proteomics》2010,10(21):3789-3799
Resistance to platinum-based chemotherapy is the major obstacle to successful treatment of ovarian cancer. It is evident that mitochondrial defects and the dysfunctions of oxidative phosphorylation and energy production in ovarian cancer cells were directly related to their resistance to platinum drugs. Using 2-D DIGE, we compared mitochondrial proteins from two platinum-sensitive human ovarian cancer cell lines (SKOV3 and A2780) with that of four platinum-resistant sublines (SKOV3/CDDP, SKOV3/CBP, A2780/CDDP, and A2780/CBP). Among the 236 differentially expressed spots, five mitochondrial proteins (ATP-α, PRDX3, PHB, ETF, and ALDH) that participate in the electron transport respiratory chain were identified through mass spectrometry. All of them are downregulated in one or two of the platinum-resistant cell lines. Three proteins (ATP-α, PRDX3, and PHB) were validated by using western blot and immunohistochemistry. There is a significant decrease of PHB in tumor tissues from ovarian cancer patients who were resistant to platinum-based chemotherapies. This is the first direct mitochondrial proteomic comparison between platinum-sensitive and resistant ovarian cancer cells. These studies demonstrated that 2-D DIGE-based proteomic analysis could be a powerful tool to investigate limited mitochondrial proteins, and the association of PHB expression with platinum resistance indicates that mitochondria defects may contribute to platinum resistance in ovarian cancer cells.  相似文献   

16.
Although cisplatin derivatives are first line chemotherapeutic agents for the treatment of ovarian epithelial cancer, chemoresistance is a major therapeutic problem. Although the cytotoxic effect of these agents are believed to be mediated through the induction of apoptosis, the role of the Fas/FasL system in chemoresistance in human ovarian epithelial cancer is not fully understood. In the present study, we have used cultures of established cell lines of cisplatin-sensitive human ovarian epithelial tumours (OV2008 and A2780-s) and their resistant variants (C13* and A2780-cp, respectively) to assess the role ofFas/FasL system in the chemo-responsiveness of ovarian cancer cells to cisplatin. Cisplatin was effective in inducing the expression of cell-associated Fas and FasL, soluble FasL and apoptosis in concentration and time-dependent fashion in both cisplatin-sensitive cell lines (OV2008 and A2780-s). In contrast, while cisplatin was effective in increasing cell-associated Fas protein content in C13*, it failed to up-regulate FasL (cell-associated and soluble forms) and induce apoptosis, irrespective of concentration and duration of cisplatin treatment. Concentrated spent media from OV2008 cultures after cisplatin treatment were effective in inducing apoptosis in C13* cells which was partly inhibited by the antagonistic Fas monoclonal antibody (mAb) suggesting that the soluble FasL present in the spent media was biologically active. In the resistant A2780-cp cells, neither Fas nor FasL up-regulation were evident in the presence of the chemotherapeutic agent and apoptosis remained low compared to its sensitive counterpart. Activation of the Fas signalling pathway, by addition to the cultures an agonistic Fas mAb, was equally effective in inducing apoptosis in the cisplatin-sensitive (OV2008) and -resistant variant C13*, although these responses were of lower magnitude compared to that observed with cisplatin in the chemosensitive cells. A significant interaction between cisplatin and agonistic Fas mAb was observed in the apoptotic response in OV2008 and C13* when cultured in the presence of both agents. Immunohistochemistry of human ovarian epithelial carcinomas reveals the presence of Fas in low abundance in proliferatively active cells but in high levels in quiescent ones. Although the expression pattern of FasL in the tumour was similar to that of Fas, the protein content was considerably lower. Taken together, these data suggest that the dysregulation of the Fas/FasL system may be an important determinant in cisplatin resistance in ovarian epithelial cancer cells. Our results are also supportive of the notion that combined immuno- and chemo-therapy (i.e., agonistic Fas mAb plus cisplatin) may provide added benefits in the treatment of both chemo-sensitive and -resistant ovarian tumours.  相似文献   

17.
18.
Three new asymmetric platinum(II) complexes comprising an isopropylamine ligand trans to an azole ligand were synthesized and fully characterized by 1H NMR, 195Pt NMR, IR and elemental analysis. In addition the X-ray crystal structure of all three complexes was determined. The reaction kinetics of the complexes with DNA model base guanosine-5′-monophosphate (GMP) was studied, revealing reaction kinetics comparable to cisplatin. To gain insight in the complexes as potential antitumor agents, cytotoxicity assays were performed on a variety of human tumor cell lines. These assays showed the complexes all to possess cytotoxicity profiles comparable to cisplatin. Furthermore, the complexes largely retain their activity in a human ovarian carcinoma cell line resistant to cisplatin, A2780R, compared to the cisplatin sensitive parent cell line A2780. These results are of fundamental importance, illustrating how platinum complexes of trans geometry can show improved activity compared to cisplatin in both cisplatin sensitive and cisplatin resistant cell lines.  相似文献   

19.
Three new asymmetric platinum(II) complexes comprising an isopropylamine ligand trans to an azole ligand were synthesized and fully characterized by 1H NMR, 195Pt NMR, IR and elemental analysis. In addition the X-ray crystal structure of all three complexes was determined. The reaction kinetics of the complexes with DNA model base guanosine-5′-monophosphate (GMP) was studied, revealing reaction kinetics comparable to cisplatin. To gain insight in the complexes as potential antitumor agents, cytotoxicity assays were performed on a variety of human tumor cell lines. These assays showed the complexes all to possess cytotoxicity profiles comparable to cisplatin. Furthermore, the complexes largely retain their activity in a human ovarian carcinoma cell line resistant to cisplatin, A2780R, compared to the cisplatin sensitive parent cell line A2780. These results are of fundamental importance, illustrating how platinum complexes of trans geometry can show improved activity compared to cisplatin in both cisplatin sensitive and cisplatin resistant cell lines.  相似文献   

20.
In the present study, we investigated the in vitro antitumor functions of a synthetic chalcone derivative 4,3′,4′,5′- tetramethoxychalcone (TMOC) in ovarian cancer cells. We found that TMOC inhibited the proliferation and colony formation of cisplatin sensitive cell line A2780 and resistant cell line A2780/CDDP, as well as ovarian cancer cell line SKOV3 in a time- and dose-dependent manner. Treatment of A2780 cells with TMOC resulted in G0/G1 cell cycle arrest through the down-regulation of cyclin D1 and CDK4, and the up-regulation of p16, p21 and p27 proteins. We demonstrated that TMOC might induce cell apoptosis through suppressing Bcl-2 and Bcl-xL, but enhancing the expression of Bax and the cleavage of PARP-1. Treatment of TMOC also reduced the invasion and migration of A2780 cells. Finally, we found that TMOC inhibited the constitutive activation of STAT3 signaling pathway and induced the expression of the tumor suppressor PTEN regardless of the p53 status in cell lines. These data suggest that TMOC may be developed as a potential chemotherapeutic agent to effectively treat certain cancers including ovarian cancer.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号